Diagnosing COPD: High Time for a Paradigm Shift

References

1. 1.↵
   1. Vaz Fragoso CA,
   2. Gill TM,
   3. McAvay G,
   4. Van Ness PH,
   5. Yaggi HK,
   6. Concato J

   . Use of lambda-mu-sigma-derived z score for evaluating respiratory impairment in middle-aged persons. Respir Care 2011;56(11):1771–1777

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Aggarwal AN,
   2. Gupta D,
   3. Agarwal R,
   4. Jindal SK

   . Comparison of the lower confidence limit to the fixed-percentage method for assessing airway obstruction in routine clinical practice. Respir Care 2011;56(11):1778–1784.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management and Prevention of COPD. Update 2010. http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. Accessed September 7, 2011.
4. 4.↵
   American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991;144(5 part 1):1202–1218.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.
   1. Quanjer PH,
   2. Tammeling GJ,
   3. Cotes JE,
   4. Pedersen OF,
   5. Peslin R,
   6. Yernault J-C

   . Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal, Official Statement of the European Respiratory Society. Eur Respir J 1993;6(Suppl 16):5–40.

   OpenUrlFREE Full Text
6. 6.↵
   1. Miller MR,
   2. Hankinson J,
   3. Brusasco V,
   4. Burgos F,
   5. Casaburi R,
   6. Coates A,
   7. et al

   ; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005;26(2):319–338.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Levy ML,
   2. Quanjer PH,
   3. Booker R,
   4. Cooper BG,
   5. Holmes S,
   6. Small I

   . Diagnostic spirometry in primary care: proposed standards for general practice compliant with American Thoracic Society and European Respiratory Society recommendations: a General Practice Airways Group (GPIAG) document, in association with the Association for Respiratory Technology & Physiology (ARTP) and Education for Health. Prim Care Respir J 2009;18(3):130–147.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Bates DV,
   2. Christie RV

   . Respiratory function in disease. Philadelphia: Saunders; 1964:91
9. 9.↵
   1. Sobol BJ

   . Assessment of ventilatory abnormality in the asymptomatic subject: an exercise in futility. Thorax 1966;21(5):445–449.

   OpenUrlFREE Full Text
10. 10.↵
    1. Miller MR,
    2. Pincock AC

    . Predicted values: how should we use them? (editorial) Thorax 1988;43(4):265–267.

    OpenUrl
11. 11.↵
    1. Sobol BJ,
    2. Sobol PG

    . Per cent of predicted as the limit of normal in pulmonary function testing: a statistically valid approach (editorial). Thorax 1979;34(1):1–3.

    OpenUrlFREE Full Text
12. 12.↵
    1. Hardie JA,
    2. Buist AS,
    3. Vollmer WM,
    4. Ellingsen I,
    5. Bakke PS,
    6. Mørkve O

    . Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002;20(5):1117–1122.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Cerveri I,
    2. Corsico AG,
    3. Accordini S,
    4. Niniano R,
    5. Ansaldo E,
    6. Antó JM,
    7. et al

    . Underestimation of airflow obstruction among young adults using FEV₁/FVC < 70% as a fixed cut-off; a longitudinal evaluation of clinical and functional outcomes. Thorax 2008;63(12):1040–1045.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Hoesein FAAM,
    2. Zanen P,
    3. Lammers J-WJ

    . Lower limit of normal or FEV₁/FVC <0.70 in diagnosing COPD: an evidence-based review. Respir Med 2011;105(6):907–915.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Mannino DM,
    2. Buist AS,
    3. Vollmer WM

    . Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax 2007;62(3):237–241.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Mannino DM,
    2. Buist AS,
    3. Vollmer WM

    . Authors' reply to two letters to the editor. Thorax 2007;62(12):1108–1109.

    OpenUrlFREE Full Text
17. 17.↵
    1. Garcia-Aymerich J,
    2. Pons IS,
    3. Mannino DM,
    4. Maas AK,
    5. Miller DP,
    6. Davis KJ

    . Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax 2011;66(7):85–590.

    OpenUrl
18. 18.↵
    1. Mannino DM

    . Understanding COPD hospitalizations: the devil is always in the details! Chest 2007;132(60):1731–1732.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Damarla M,
    2. Celli BR,
    3. Mullerova HX,
    4. Pinto-Plata VM

    . Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respir Care 2006;51(10):1120–1124.

    OpenUrlPubMedWeb of Science
20. 20.↵
    1. Ekberg-Aronsson M,
    2. Pehrsson K,
    3. Nilsson JÅ,
    4. Nilsson PM,
    5. Löfdahl CG

    . Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 2005;6(1):98.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Vaz Fragoso CA,
    2. Concato J,
    3. McAvay G,
    4. Van Ness PH,
    5. Rochester CL,
    6. Klar Yaggi H,
    7. Gill TM

    . Chronic obstructive pulmonary disease in older persons: a comparison of two spirometric definitions. Respir Med 2010;104(8):1189–1196.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Miller MR,
    2. Pedersen OF,
    3. Dirksen A

    . A new staging strategy for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2007;2(4):657–663.

    OpenUrlPubMed
23. 23.↵
    1. Bridevaux PO,
    2. Gerbase MW,
    3. Probst-Hensch NM,
    4. Schindler C,
    5. Gaspoz JM,
    6. Rochat T

    . Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax 2008;63(9):768–774.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Miller MR,
    2. Quanjer PH,
    3. Swanney MP,
    4. Ruppel G,
    5. Enright PL

    . Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. Chest 2011;139(1):52–59.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Vaz Fragoso CA,
    2. Concato J,
    3. McAvay G,
    4. Van Ness PH,
    5. Rochester C,
    6. Klar Yaggi H,
    7. Gill TM

    . The ratio of forced expiratory volume in 1-second to forced vital capacity as a basis for establishing chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181(5):446–451.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Stanojevic S,
    2. Wade A,
    3. Stocks J,
    4. Hankinson J,
    5. Coates AL,
    6. Pan H,
    7. et al

    . Reference ranges for spirometry across all ages. Am J Respir Crit Care Med 2008;177(3):253–260.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Stanojevic S,
    2. Wade A,
    3. Stocks J

    . Reference values for lung function: past, present and future. Eur Respir J 2010;36(1):12–19.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    1. Quanjer PH,
    2. Enright PL,
    3. Ruppel G

    . The GOLD guidelines definition of mild airway obstruction. Respir Care 2010;55(10):1397–1398.

    OpenUrlFREE Full Text
29. 29.↵
    1. Quanjer PH,
    2. Enright PL,
    3. Miller MR,
    4. Stocks J,
    5. Ruppel G,
    6. Swanney MR,
    7. et al

    . The need to change the method for defining mild airway obstruction. Eur Respir J 2011;37(3):720–722.

    OpenUrlFREE Full Text
30. 30.↵
    1. Vestbo J,
    2. Rodriguez-Roisin R

    . GOLD and the fixed ratio. Eur Respir J 2011;38(2):481–482.

    OpenUrlFREE Full Text
31. 31.↵
    1. Quanjer PH,
    2. Enright PL,
    3. Ruppel G,
    4. Miller MR,
    5. Vaz Fragoso CA,
    6. Cooper BG,
    7. et al

    . GOLD and the fixed ratio. Eur Respir J 2011;38(2):482–483.

    OpenUrlFREE Full Text
32. 32.↵
    1. Qaseem A,
    2. Wilt TJ,
    3. Weinberger SE,
    4. Hanania NA,
    5. Criner G,
    6. van der Molen T,
    7. et al

    . Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155(3):179–191.

    OpenUrlCrossRefPubMedWeb of Science
33. 33.↵
    1. Sorlie PD,
    2. Kannel WB,
    3. O'Connor G

    . Mortality associated with respiratory function and symptoms in advanced age. The Framingham Study. Am Rev Respir Dis 1989;140(2):379–384.

    OpenUrlPubMedWeb of Science
34. 34.
    1. Hole DJ,
    2. Watt GCM,
    3. Davey-Smith G,
    4. Hart CL,
    5. Gillis CR,
    6. Hawthorne VM

    . Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996;313(7059):711–715.

    OpenUrlAbstract/FREE Full Text
35. 35.
    1. Knuiman MW,
    2. James AL,
    3. Divitini ML,
    4. Ryan G,
    5. Bartholomew HC,
    6. Musk AW

    . Lung function, respiratory symptoms, and mortality: results from the Busselton health study. Ann Epidemiol 1999;9(5):297–306.

    OpenUrlCrossRefPubMedWeb of Science
36. 36.↵
    1. Sin DD,
    2. Wu LL,
    3. Paul Man SFP

    . The relationship between reduced lung function and cardiovascular mortality. A population-based study and a systematic review of the literature. Chest 2005;127(6):1952–1959.

    OpenUrlCrossRefPubMedWeb of Science